BCAX vs. CADL

Last updated Apr 1, 2026

Compare and contrast key facts about Bicara Therapeutics Inc (BCAX) and Candel Therapeutics, Inc. (CADL).

Performance

BCAX vs. CADL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bicara Therapeutics Inc (BCAX) and Candel Therapeutics, Inc. (CADL). The values are adjusted to include any dividend payments, if applicable.

BCAX vs. CADL - Yearly Performance Comparison

	2026 (YTD)	2025	2024
BCAX Bicara Therapeutics Inc	18.18%	-3.39%	-25.59%
CADL Candel Therapeutics, Inc.	-13.27%	-34.91%	23.82%

Fundamentals

Market Cap BCAX : $1.10B CADL : $269.00M
EPS BCAX : -$2.52 CADL : -$0.16
PB Ratio BCAX : 2.73 CADL : 5.18
Total Revenue (TTM) BCAX : $0.00 CADL : $0.00
Gross Profit (TTM) BCAX : $0.00 CADL : -$682.00K
EBITDA (TTM) BCAX : -$151.12M CADL : -$23.05M

Returns By Period

In the year-to-date period, BCAX achieves a 18.18% return, which is significantly higher than CADL's -13.27% return.

BCAX

• 1D: 4.46%
• 1M: 18.53%
• YTD: 18.18%
• 6M: 25.97%
• 1Y: 52.65%
• 3Y*: —
• 5Y*: —
• 10Y*: —

CADL

• 1D: 9.38%
• 1M: -6.67%
• YTD: -13.27%
• 6M: -3.92%
• 1Y: -13.27%
• 3Y*: 53.68%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

BCAX vs. CADL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

BCAX

BCAX Risk / Return Rank: 64
BCAX Sharpe Ratio Rank: 63
BCAX Sortino Ratio Rank: 63
BCAX Omega Ratio Rank: 66
BCAX Calmar Ratio Rank: 64
BCAX Martin Ratio Rank: 62

CADL

CADL Risk / Return Rank: 31
CADL Sharpe Ratio Rank: 33
CADL Sortino Ratio Rank: 35
CADL Omega Ratio Rank: 34
CADL Calmar Ratio Rank: 27
CADL Martin Ratio Rank: 27

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BCAX vs. CADL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bicara Therapeutics Inc (BCAX) and Candel Therapeutics, Inc. (CADL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	BCAX	CADL	Difference
Sharpe ratio Return per unit of total volatility	0.64	-0.19	+0.82
Sortino ratio Return per unit of downside risk	1.33	0.23	+1.10
Omega ratio Gain probability vs. loss probability	1.19	1.03	+0.17
Calmar ratio Return relative to maximum drawdown	1.09	-0.47	+1.57
Martin ratio Return relative to average drawdown	2.28	-0.86	+3.14
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

BCAX vs. CADL - Sharpe Ratio Comparison

The current BCAX Sharpe Ratio is 0.64, which is higher than the CADL Sharpe Ratio of -0.19. The chart below compares the historical Sharpe Ratios of BCAX and CADL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	BCAX	CADL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.64	-0.19	+0.82
Sharpe Ratio (All Time) Calculated using the full available price history	-0.13	-0.04	-0.08

Correlation

The correlation between BCAX and CADL is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

BCAX vs. CADL - Dividend Comparison

Neither BCAX nor CADL has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

BCAX vs. CADL - Drawdown Comparison

The maximum BCAX drawdown since its inception was -67.82%, smaller than the maximum CADL drawdown of -94.33%. Use the drawdown chart below to compare losses from any high point for BCAX and CADL.

Drawdown Indicators

	BCAX	CADL	Difference
Max Drawdown Largest peak-to-trough decline	-67.82%	-94.33%	+26.51%
Max Drawdown (1Y) Largest decline over 1 year	-44.38%	-37.04%	-7.34%
Current Drawdown Current decline from peak	-26.52%	-65.00%	+38.48%
Average Drawdown Average peak-to-trough decline	-42.47%	-63.27%	+20.80%
Ulcer Index Depth and duration of drawdowns from previous peaks	21.23%	20.47%	+0.76%

Volatility

BCAX vs. CADL - Volatility Comparison

The current volatility for Bicara Therapeutics Inc (BCAX) is 12.58%, while Candel Therapeutics, Inc. (CADL) has a volatility of 18.36%. This indicates that BCAX experiences smaller price fluctuations and is considered to be less risky than CADL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BCAX	CADL	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.58%	18.36%	-5.78%
Volatility (6M) Calculated over the trailing 6-month period	44.11%	49.60%	-5.49%
Volatility (1Y) Calculated over the trailing 1-year period	83.30%	71.34%	+11.96%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	80.18%	169.43%	-89.25%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	80.18%	169.43%	-89.25%

Financials